Gilead Sciences Inc (GILD)
66.50
+0.34
(+0.51%)
USD |
NASDAQ |
Apr 19, 12:54
Gilead Sciences Cash from Operations (TTM): 8.006B for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 8.006B |
September 30, 2023 | 8.404B |
June 30, 2023 | 9.512B |
March 31, 2023 | 8.976B |
December 31, 2022 | 9.072B |
September 30, 2022 | 9.71B |
June 30, 2022 | 10.10B |
March 31, 2022 | 10.61B |
December 31, 2021 | 11.38B |
September 30, 2021 | 10.10B |
June 30, 2021 | 9.092B |
March 31, 2021 | 9.342B |
December 31, 2020 | 8.168B |
September 30, 2020 | 8.832B |
June 30, 2020 | 9.227B |
March 31, 2020 | 9.003B |
December 31, 2019 | 9.144B |
September 30, 2019 | 8.909B |
June 30, 2019 | 8.476B |
March 31, 2019 | 7.707B |
December 31, 2018 | 8.40B |
September 30, 2018 | 8.808B |
June 30, 2018 | 9.29B |
March 31, 2018 | 11.24B |
December 31, 2017 | 11.90B |
Date | Value |
---|---|
September 30, 2017 | 12.68B |
June 30, 2017 | 14.38B |
March 31, 2017 | 15.84B |
December 31, 2016 | 17.05B |
September 30, 2016 | 19.30B |
June 30, 2016 | 19.01B |
March 31, 2016 | 19.68B |
December 31, 2015 | 21.25B |
September 30, 2015 | 18.48B |
June 30, 2015 | 18.42B |
March 31, 2015 | 16.95B |
December 31, 2014 | 12.82B |
September 30, 2014 | 10.52B |
June 30, 2014 | 7.233B |
March 31, 2014 | 4.001B |
December 31, 2013 | 3.105B |
September 30, 2013 | 3.084B |
June 30, 2013 | 3.076B |
March 31, 2013 | 3.414B |
December 31, 2012 | 3.195B |
September 30, 2012 | 3.467B |
June 30, 2012 | 3.619B |
March 31, 2012 | 3.271B |
December 31, 2011 | 3.639B |
September 30, 2011 | 3.386B |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
8.006B
Minimum
Dec 2023
11.38B
Maximum
Dec 2021
9.267B
Average
9.092B
Median
Jun 2021
Cash from Operations (TTM) Benchmarks
Amgen Inc | 8.471B |
Johnson & Johnson | 22.79B |
Eli Lilly and Co | 4.240B |
CymaBay Therapeutics Inc (DELISTED) | -72.53M |
Arcus Biosciences Inc | -306.00M |